CONNECT WITH US
HealthTech

HealthTech

Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma

Medical Xpress logo

Published on

Add as a preferred source on Google
Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL—short for trimeric APRIL (a proliferation-inducing ligand)—recognizes two proteins on myeloma cells instead of just one. Researchers published their findings in The Lancet.

Multiple myeloma is a cancer of plasma cells, which are immune cells that make antibodies. To create CAR T-cell therapy, scientists modify a patient's T cells so they can find and attack myeloma cells. Existing CAR T-cell therapies recognize B-cell maturation antigen (BCMA) on myeloma cells. TriPRIL was engineered by Mass General Brigham researchers to make the CAR-T cells recognize both BCMA and a second protein, transmembrane activator and CAML interactor (TACI).

Because the treatment is based on human proteins, the researchers believe it may be less likely to lead to anti-drug antibodies that can reduce the long-term persistence and effects of other CAR-T cells.

"BCMA-targeted CAR T-cell therapy has transformed multiple myeloma treatment, but most patients eventually relapse," said co-senior author Marcela V. Maus, M.D., Ph.D., director of the Mass General Brigham Cancer Institute's Cellular Immunotherapy Program. "TriPRIL adds TACI as a second target, allowing it to find and attack myeloma cells, even if they stop expressing BCMA."

The Phase I TriPRIL trial treated 15 patients at the Mass General Brigham Cancer Institute whose multiple myeloma had come back despite many treatments.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.